Triptolide Administration Alters Immune Responses to Mitigate Insulin Resistance in Obese States

Lyudmila Grodsky,Mickey Wilson,Thirumurugan Rathinasabapathy,Slavko Komarnytsky
DOI: https://doi.org/10.3390/biom14040395
IF: 6.064
2024-03-26
Biomolecules
Abstract:Individuals who are overweight or obese are at increased risk of developing prediabetes and type 2 diabetes, yet the direct molecular mechanisms that connect diabetes to obesity are not clear. Chronic, sustained inflammation is considered a strong risk factor in these interactions, directed in part by the short-lived gene expression programs encoding for cytokines and pro-inflammatory mediators. In this study, we show that triptolide administration in the C57BL/6 diet-induced obese mice at up to 10 μg/kg/day for 10 weeks attenuated the development of insulin resistance and diabetes, but not obesity, in these animals. Significant reductions in adipose tissue inflammation and improved insulin sensitivity were observed in the absence of changes in food intake, body weight, body composition, or energy expenditure. Analysis of the core cluster of biomarkers that drives pro-inflammatory responses in the metabolic tissues suggested TNF-α as a critical point that affected the co-development of inflammation and insulin resistance, but also pointed to the putatively protective roles of increased COX-2 and IL-17A signaling in the mediation of these pathophysiological states. Our results show that reduction of diet-induced inflammation confers partial protection against insulin resistance, but not obesity, and suggest the possibility of achieving overweight phenotypes that are accompanied by minimal insulin resistance if inflammation is controlled.
biochemistry & molecular biology
What problem does this paper attempt to address?
The problem this paper attempts to address is how the administration of Triptolide alleviates insulin resistance in the context of obesity by altering immune responses. The study found that in a high-fat diet-induced mouse model of obesity, Triptolide significantly reduces insulin resistance without affecting obesity itself. Specifically, Triptolide can reduce adipose tissue inflammation and improve insulin sensitivity, and these effects are independent of changes in food intake, body weight, body composition, or energy expenditure. The study also found that tumor necrosis factor-α (TNF-α) plays a key role in the co-development of inflammation and insulin resistance, and it suggests that increased cyclooxygenase-2 (COX-2) and interleukin-17A (IL-17A) signaling may have protective effects. In summary, by controlling inflammation, a minimized insulin resistance overweight phenotype can be achieved.